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Ebola virus-speciﬁc neutralizing antibodieswere induced in nearly all individuals. Additionally, vaccinees, partic-
ularlywithin the highest dose cohort, generated Ebola glycoprotein (GP)-speciﬁc T cells and initiated a cascade of
signaling molecules following stimulation of peripheral blood mononuclear cells with Ebola GP peptides.
Interpretation: In addition to a benign safety and robust humoral immunogenicity proﬁle, subjects immunized
with 2 × 107 PFU elicited higher cellular immune responses and stronger interlocked cytokine networks com-
pared to lower dose groups. To our knowledge these data represent the ﬁrst detailed cell-mediated
immuneproﬁle of a clinical trial testing rVSV-ZEBOV,which is of particular interest in light of its potential upcom-
ing licensure as the ﬁrst Ebola vaccine.
VEBCON trial Hamburg, Germany (NCT02283099).©2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The recentWest African Ebola virus (EBOV) outbreakwas the largest
outbreak in the history of Ebola virus disease (EVD) with N28,600 con-
ﬁrmed infections and over 11,300 fatalities (WHO Situation Report,
March 2016). This dramatic health crisis was in part facilitated by the
lack of licensed medical countermeasures. Following theWHO declara-
tion of the outbreak as a Public Health Emergency of International Con-
cern, clinical studies of Ebola vaccine candidates were accelerated
(Pavot, 2016), including rVSV-ZEBOV (recombinant vesicular stomatitis
virus-vectored Ebola vaccine).
As part of the WHO-led VSV-Ebola consortium (VEBCON) we con-
ducted a phase I trial to test rVSV-ZEBOV in 30 healthy subjects using
three dosage levels (3 × 105, 3 × 106 and 2 × 107 plaque forming units
(PFU). The vaccine subsequently proceeded into a phase III trial (Ebola
ça sufﬁt!) demonstrating high efﬁcacy in reduction of human-to-
human transmission following rVSV-ZEBOV immunization (Henao-
Restrepo et al., 2017). The priority licensing process is currently under-
waywith anticipated licensure in 2017. Nevertheless, no human immu-
nological correlate of protection exists and mechanisms of immune
responses elicited by rVSV-ZEBOV remain incompletely understood.
rVSV-ZEBOV (serotype Indiana) is genetically modiﬁed to encode
Ebola glycoprotein (GP) instead of the VSVwildtype GP (Geisbert and
Feldmann, 2011). Several animalmodels revealed protection after lethal
challenges with EBOV (Wong et al., 2014; Jones et al., 2005;Marzi et al.,
2016; de Wit et al., 2015; Qiu et al., 2009). Non-human primate (NHP)
studies demonstrated 100% protection after a single dose of rVSV-
ZEBOV (Jones et al., 2005), whereas 50% protection was achieved
when it was used as post-exposure prophylaxis (PEP) (Feldmann et
al., 2007), suggesting rVSV-ZEBOV as a suitable vaccine candidate dur-
ing outbreak scenarios.
Mechanisms underlying rVSV-ZEBOV mediated protection are not
completely understood thus far. Antibody responses have been correlat-
ed with protection in animal models, but could not be demonstrated as
surrogate of protection (Marzi et al., 2013; Geisbert et al., 2008;Wonget
al., 2012; Jones et al., 2005). The impact of antigen-speciﬁc T-cell re-
sponses in humans following rVSV-ZEBOV vaccination has not been in-
vestigated comprehensively (Pavot, 2016). To date, only one case
report, in which rVSV-ZEBOV was used as PEP, reported on lymphocyte
dynamics and cellular immunity (Lai et al., 2015). Another study charac-
terized circulating follicular T-helper cells induced by rVSV-ZEBOV vac-
cination in healthy adults (Farooq et al., 2016). While experimental
evidence for T-cell mediated protection from animal models exist
(Wilson andHart, 2001;Wonget al., 2012),more data are needed to un-
derstand the contribution of cell-mediated immunity, and speciﬁcally
Ebola-speciﬁc T cells induced by rVSV-ZEBOV for protection against
EVD.
Our detailed immune proﬁle revealed increased induction of cell-
mediated Ebola-speciﬁc immune responses and broader secretion of
signalingmolecules in subjects immunized with 2 × 107 PFU compared
to subjects of the two lower dose groups. Ebola-speciﬁc T cells were de-
tectable, albeit at moderate to low magnitude and with CD8+ T-cellpredominance in this study. Our data support the dosage of 2 × 107
PFU, as used in the Ebola ça sufﬁt! trial and provide comprehensive
novel human information of immune responses elicited by rVSV-
ZEBOV.2. Methods
2.1. Study Design and Participants
NCT02283099 was an open label, phase I investigator initiated trial
(IIT) of single-escalating doses of rVSV–ZEBOV (BPSC 1001, also referred
to as V920) in healthy adults aged 18 to 55 years. Full details regarding
entry criteria and procedures are provided in the studyprotocol (Supple-
mentary Appendix) and have been described previously (Agnandji et al.,
2016). The study was reviewed and approved by the ethics committee,
the German authority for genetic engineering, and the WHO research
ethics review committee. This study was performed in accordance with
the Declaration of Helsinki in its version of Seoul 2008. All participants
provided written informed consent. (ClinicalTrials.gov; NCT02283099;
Phase I Trial to Assess Safety, Tolerability, and Immunogenicity of Ebola
Virus Vaccine).2.2. Vaccination
The vaccine was developed by New Link Genetics Corporation and
the Government of Canada, and manufactured by IDT Biologica GmbH
(Dessau, Germany). Injections were administered intramuscularly into
the deltoid. Dose-escalation studies were performed in a staggered
manner for safety. Participants received doses of 3 × 105, 3 × 106 or 2
× 107 PFU. The vaccination protocol was performed as previously de-
scribed (Agnandji et al., 2016).2.3. Safety Monitoring
Local and systemic reactogenicitywere recorded for 7 days on a daily
notiﬁcation sheet after vaccination and were reported further on fol-
low-up visits. Safetymonitoringwas performed as previously described
(Agnandji et al., 2016).2.4. Immunogenicity
Sera were collected to perform enzyme-linked immunosorbent
assay (ELISA) for EBOV GP-speciﬁc antibodies using inactivated whole
virions of the Zaire-Guéckédou strain. Neutralizing antibodies were de-
tected using VSV-pseudovirions expressing the luciferase reporter gene,
or by using infectious EBOV-isolate (Mayinga). The latter one was done
with sera starting with a dilution of 1:8. Seropositivity is deﬁned by a
GMT b 8. The assays were performed as previously reported (Agnandji
et al., 2016; Krahling et al., 2016).
Table 1
Patient characteristics at baseline. Characteristics of individuals at baseline.
Cohort 1
3 × 105 PFU
Cohort 2
3 × 106 PFU
Cohort 3
2 × 107 PFU
Sex\\no. (%)
Male 7 (70) 6 (60) 7 (70)
Female 3 (30) 4 (40) 3 (30)
Age\\years
Mean 44 ± 11 32 ± 8 40 ± 9
Range 23–54 24–47 24–51
Race\\no. (%)
Asian 0 1 (10) 0
White 10 (100) 9 (90) 10 (100)
Body-mass index 27 ± 3 25 ± 3 24 ± 3
Plus-minus values are means ± SD.
Race was self-reported.
The Body-mass index is the weight in kilograms divided by the square of the height in
meters.
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Peripheral blood mononuclear cells (PBMCs) were isolated and
cryopreserved from EDTA-blood using standard operating procedures
via ﬁcoll density gradient centrifugation. Phenotypic properties of T
and B cells were analyzed by ﬂow cytometry using LSRFortessa (BD Bio-
science) and evaluated with FlowJo10. Flow cytometry gating strategy
and the corresponding used antibodies are shown in the Supplementary
Appendix.
2.6. Ebola-speciﬁc T-cell Responses
Antigen-speciﬁc T cells were analyzed using cryopreserved PBMCs.
Following overnight resting, PBMCs were incubated for 6 h at 37 °C
with overlapping peptide pools (OLPs) spanning the aa sequence of
Ebola GP (Kikwit-strain, sequences: Supplementary Appendix: Peptide
pool) in thepresence of CD28/CD49d, GolgiStop andGolgiPlug. Negative
controls were treated with RPMI1640 (10% FCS supplemented with
DMSO). PMA and CEF (CMV,EBV,Inﬂuenza-peptides) served as positive
controls. We used IC ﬁxation and Perm buffer (affymetrix ebioscience)
to analyze the expression of tumor necrosis factorα (TNFα), interleukin
2 (IL2), macrophage inﬂammatory protein 1β (MIP1β) and interferon γ
(IFNγ); and stained also against CD107a. Cells were analyzed on
LSRFortessa (BD Bioscience) and evaluated with FlowJo10. Gating strat-
egy and corresponding antibody panels are depicted in the Supplemen-
tary Appendix S1 and Table S3. Polyfunctionality was analyzed using
Boolean gating. The measured values were subtracted for each sample
with the corresponding DMSO control.
2.7. Measurement of Cytokines, Chemokines and Growth Factors
Ebola GP-speciﬁc cellular responses were assessed using Ebola GP
OLPs by IFNγ-ELISpot (MabtechELISpotPLUS). Cryopreserved PBMCs
were rested for 4 h followed by 16 h stimulation with peptide pools.
We used 125,000 cells/well and performed theELISpot as previously de-
scribed (Dahlke et al., 2017). PHA and CD3 were used as positive con-
trols, RPMI1640 (10%FCS supplemented with DMSO) served as
negative control.
Cytokines, chemokines and growth factors weremeasured using su-
pernatant of the ELISpot assay, which was collected 16 h after stimula-
tion. Samples were analyzed using a 27plex-BioRad-LUMINEX assay
following themanufacturers instructions. Variableswere ordered by hi-
erarchical clustering with hclust provided with complete as agglomera-
tion method. R (3.3.2) (https://www.R-project.org/) was applied for
calculation of the correlations and plotting. Correlations were plotted
using package corrplot (0.77) (https://CRAN.R-project.org/package=
corrplot), the heatmap was plotted using package pheatmap (1.0.8)
(https://CRAN.R-project.org/package=pheatmap).
2.8. Data Analysis
Frequencies of adverse events (AEs) and serious adverse events
(SAEs) were determined per dose group. We employed Fisher's exact
test, Mann-Whitney-Wilcoxon, Kruskal-Wallis test to calculate intra-
and inter-group associations as appropriate. Analyses were performed
in Prism (v7.0a, GraphPad Software, San Diego, CA).
3. Results
3.1. Study Participants
A total of 30 participants were vaccinated at the University Medical
Center Hamburg Eppendorf (UKE) between November 17, 2014 and
May 5, 2015. The study population consisted of 20 men and 10
women with a mean age of 38.8 years (range: 23–54 years) (Table 1).
29 participants were of European, one was of Asian descent. Thefollow-up visits were attended by all participants except one, who
exited the study after day 28 (Fig. 1). Clinical data of part of the study
population were reported previously (Agnandji et al., 2016). We here
present the complete data set of the Hamburg VEBCON study site.
3.2. rVSV-ZEBOV Exhibits a Benign Safety Proﬁle
In the ﬁnal analysis of the complete Hamburg cohort, no vaccine-re-
lated SAEs or AEs resulting inwithdrawal from the studywere observed.
During the six month follow-up, all participants (except one) experi-
enced AEs. Themajority of AEs (104)were classiﬁed asmild, 20 asmod-
erate and three as severe (neck-tension, myalgia and fatigue) (Fig. 2a,
neck tension is excluded from Fig. 2a as it was a single event). All of
them were transient (mean duration was 2.14 days, 95% CI 1.80–2.48).
Themost frequent AEswere pain at the injection site,myalgia and head-
ache. Solicited local reactogenicity was common but generally mild.
Fever, but also viremia and lymphopenia had been observed in the
two higher dose groups, but not in subjects immunized with the lowest
dose (Supplementary Appendix, Figs. S2, S3 and Tables S5, S6).
The majority of AEs occurred within the ﬁrst week post vaccination
(Fig. 2b). Subjects of the two higher dose cohorts reported a higher
number of AEs during the ﬁrst four days with a peak at day 1 and 2
post vaccination compared to the lowest dose group, which overall ex-
perienced a lower number of AEs with a peak on day 3.
Four vaccinees experienced unsolicited AEs; three cases of arthralgia
and one case of oligoarthritis were reported. They were transient and of
mild to moderate intensity. The case of oligoarthritis was observed in
the lowest dose group and had not been reported in the previous report
(Agnandji et al., 2016).
3.3. rVSV-ZEBOV Induces Neutralizing Antibody Responses
Ebola GP-speciﬁc IgG responses were assessed using three different
assays (Fig. 3 and Supplementary Appendix, Fig. S4). The ELISA with
whole inactivated Ebola virions revealed an early induction at day 14
in the highest dose cohort that persisted for six months (Fig. S4a).
Titers of neutralizing antibodies were determined using infectious
EBOV-isolate (Fig. 3a). While all subjects (100%) immunized with
2 × 107 PFU revealed a N2-fold induction to baseline, 3 × 105 and
3 × 106 PFU cohorts showed N2-fold induction in 67% and in 60% of
the subjects, respectively (Fig. 3b, fold inductions are depicted in Sup-
plementary Appendix, Table S7). The pseudovirion neutralization
assay was performed assessing 50% serum neutralization at day 0, 28
and 180 post vaccination. (Fig. 3c). This assay showed an increase of
neutralizing antibodies on day 28 that persisted until day 180, with
the notable exeption of one subject, in which a decrease to baseline
was observed. In summary, both assays showed a signiﬁcant induction
of neutralizing antibodies after any dose of rVSV-ZEBOV, but revealed
Fig. 1. Trial proﬁle. Flow diagram of screening, enrollment and vaccination in the three cohort groups. For each cohort group, 4 to 5 eligible individuals withdrew from the study. One
participant aborted the study after day 28 due to moving abroad (3 × 106 PFU). One subject missed visit day 56 (2 × 107 PFU).
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Appendix, Fig. S4).
3.4. Dynamics of Lymphocyte Responses
To date, no ﬂow cytometry data on lymphocyte dynamics and activa-
tion following vaccination in humans have been reported for rVSV-
ZEBOV vaccine trials. We therefore ﬁrst investigated B-cell dynamics via
staining CD19, CD24 and CD38 (Fig. 4a) and observed a peak in the num-
ber of plasmablasts (CD19+CD24−CD38+) at day 7 (Fig. 4b). While this
trendwas signiﬁcant in all groups (Fig. 4c), 44% of the 2 × 107 PFU cohort
showed a N2-fold induction compared to 37.5% and 10% of vaccinees of
the 3 × 106 and 3 × 105 PFU dose cohort, respectively. Nevertheless, we
identiﬁed no intergroup differences (Kruskal-Wallis test).
Next, we assessed the activation status of both CD4+ and CD8+ T
cells by staining with anti-CD38 and anti-HLA DR antibodies (Fig. 4d).
Both types of T-cell subsets showed an increased activation status at
day 7 compared to baseline (Fig. 4e), with higher activation levels in
the CD8+ T-cell compartment compared to the CD4+ T cells. All dose
groups exhibited a signiﬁcant induction of activated CD8+ T cells at
day 7 (Mann-Whitney-Wilcoxon test: 3 × 105: p value 0.004; 3 × 106:
p value 0.03; 2 × 107: p value 0.002).
3.5. rVSV-ZEBOV Induces Detectable Ebola GP-speciﬁc T-cell Responses
To investigate the presence of Ebola GP-speciﬁc cell-mediated re-
sponses following vaccination, we assessed the induction of cytokines
(TNFα, IFNγ, IL2, MIP1β) after stimulation with four OLP-pools that
cover Ebola GP (GP1a, GP1b, GP2 and SP) (Fig. 5a). Overall T-cell re-
sponses were low to moderate and predominantly observed in the
CD8+ T-cell compartment of the highest dose cohort upon stimulation
with the peptide pools GP1b and SP (GP1b: p value 0.03; SP: p value
0.03) (results from CD4+ cells are shown in the Supplementary Appen-
dix, Fig. S6). Induction of cytokine responses were predominantly in-
creased (N2 fold) from day 0 to 56 in the highest dose cohort after
stimulation, with strongest responses following GP1b stimulation. A
N2 fold induction was obsered in 85% of subjects of the highest dosecohort, while the lower dose cohorts showed this response in 14% and
10% of subjects (3 × 106 PFU, 3 × 105 PFU, respectively). We detected
no intergroup variations (Supplementary Appendix, Figs. S5 and S6).
We could not detect a signiﬁcant expansion of polyfunctional CD8+
T cells, as representatively depicted in the piecharts for the highest dose
cohort against the GP1b pool (day 56) (Fig. 5c). The largest fraction of
GP1b-speciﬁc T cells were CD8+ T cells secreting either IFNγ, TNFα or
MIP1β. The relatively low level of IFNγ secretion was validated by an
IFNγ-ELISpot, which is depicted in the Supplementary Appendix Fig. S8.
In addition to cytokine expression, we investigated CTL-responses
using a CD107a degranulation assay. In linewith the cytokine responses,
expression of CD107a by CD8+ T cells was increased at day 56 post vac-
cination in the highest dose cohort following stimulation with Ebola GP
OLP-pools (Fig. 6a). Intergroupdifferenceswere identiﬁed at day 14 and
56 post vaccination (Supplementary Appendix, Fig. S7). To analyze the
breadth of detected CTL-responses, we examined the number of pools
per subject that showed positive responses. Positivity was speciﬁed as
three times over the baseline. The breadth of the CTL-response was
greatest in subjects immunized with the highest dose (Fig. 6b).
3.6. Vaccine Dose Associates With Cytokine Secretion (Supernatant)
For the identiﬁcation of rVSV-ZEBOV induced cytokine, chemokine
and growth factor patterns, supernatant from Ebola GP OLP-stimulated
PBMCs were analyzed using a 27-plex-LUMINEX assay. This approach
allows for in-depth analysis of signaling molecules belonging to six
functional classes that mediate the immune response (chemokines,
growth factors, TH2, TH1, immunomodulation, pro-inﬂammation)
(Fig. 7a). The highest dose group induced a broad secretion proﬁle at
day 14, while the medium dose cohort showed a delayed increase at
day 28. Cytokines belonging to the TH1-response (IL2, IL7, IL15, IFNγ,
TNFα) revealed strong and early induction in subjects immunized
with 2 × 107 PFU, which is highlighted in Fig. 7b. Notably, speciﬁcally
IL2, IFNγ and TNFα revealed a signiﬁcant intergroup difference between
all dose groups at day 14 and 28 post vaccination (Kruskal-Wallis test;
see also Supplementary Appendix, Fig. S10). Strong intergroup differ-
ences were also observed for IP10 (Supplementary Appendix, Figs. S9
Fig. 2. Local and systemic adverse events. a) Recorded adverse events of vaccinees during 180 days post vaccination. Events are depicted in frequency (%) of participants among respective
cohort presenting at least one adverse event of the category. Adverse eventswith the severity ofmild,moderate and severe are grouped into grade 1, 2 and 3, respectively. Cohort 1: 3 ×105
PFU, Cohort 2: 3 × 106 PFU, Cohort 3: 2 × 107 PFU. b) Number of related solicited and unsolicited adverse events reported over time in the 3 × 105 PFU (cohort 1 (green)), 3 × 106 PFU
(cohort 2 (blue)), and 2 × 107 PFU (cohort 3 (red)) dose group.
111C. Dahlke et al. / EBioMedicine 19 (2017) 107–118and S10) showing as well signiﬁcant intra- and intergroup differences.
IP10 is one of themost potent chemokine that induces inﬂammatory re-
sponses and is discussed as a factor for immunologic enhancement
(Kang et al., 2009; Nakaya et al., 2011).
Since cytokines form a coordinating networkmediating immune re-
sponse, we further investigated speciﬁc correlations using correlogram
analysis (Fig. 8). The strongest interconnections between cytokines at
day 14 post vaccination were observed in the highest dose cohort as in-
dicated by the median correlation coefﬁcient (mcc) (2 × 107 PFU: mcc
0.52; 3 × 106 PFU: mcc 0.39; 3 × 105 PFU: mcc 0.29). While IFNγ and
TNFα were grouped into two separate clusters in the lowest dose
group, the increase of the vaccine dose established a stronger correla-
tion of these two cytokines as summarized in Fig. 8.
4. Discussion
In the aftermath of the recent EVD outbreak, signiﬁcant progress has
been made in Ebola vaccine development. rVSV-ZEBOV currentlyrepresents themost promising vaccine candidate, speciﬁcally following
recent results from the Ebola ça sufﬁt! trial suggesting a high level of ef-
ﬁcacy (Henao-Restrepo et al., 2017). While these results and the pend-
ing licensure of rVSV-ZEBOV are encouraging, the exact correlates of
immune-protection remain unknown and human immunity data on
this novel vaccine vector system are scarce.
In addition to safety and humoral responses for the complete Ham-
burg study population, to our knowledge we here report the ﬁrst com-
prehensive analysis of B- and T-cell responses, including Ebola-speciﬁc
T-cell responses following rVSV-ZEBOV immunization. The present
study provides a detailed account of lymphocyte dynamics, breadth
and magnitude of Ebola GP-speciﬁc T-cell responses and cytokine pat-
terns. The results support the use of the vaccine dose 2 × 107 PFU in
healthy adults, which corresponds to the dose administered in the re-
cent phase III clinical trial in Guinea (Henao-Restrepo et al., 2017) and
currently prepared for licensing.
As in previous studies reported by us and others, the vaccine was
found to be reactogenic, but safe and well-tolerated without vaccine-
Fig. 3. Ebola virus antibody titers increase following administration of rVSV-ZEBOV. a) Neutralizing antibodies against infectious EBOV isolateMayingawere analyzed. Analysiswas started
with a 1:8 dilution. Seropositivity is deﬁned by a GMT N 8. b) Pseudovirion neutralization assay assessing the 50% serumneutralization capacity (PsVNA50) complemented by homologous
glycoprotein. a) and b): The results are expressed in neutralization titers. Statistical analysis was performed using Mann-Whitney-Wilcoxon test (*p b 0.05; **p b 0.01; ***p b 0.005)
(Graphs: Box and Whiskers, Min to Max, Line: Median).
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edly, the higher dose cohorts (3 × 106, 2 × 107) experienced in-
creased reactogenicity peaking at days 1–2 post vaccination,
however no signiﬁcant dose-effect was detected (Fig. 2b, Kruskal-
Wallis test, 0.5 p value).
Based on this current and our previously reported data, a single im-
munization of rVSV-ZEBOV signiﬁcantly induced antibody responses in
humans, which were maintained for at least 6 months independent of
dosage level. The impact of antibodies to protect against EVD following
rVSV-ZEBOV immunization was demonstrated in a study, where rVSV-
ZEBOV immunized NHP succumbed to lethal EBOV-challenge after
loss of Ebola GP-speciﬁc antibodies following CD4+ T-cell depletion
during vaccination (Marzi et al., 2013). However, binding or neutraliz-
ing antibodies as sole immune correlates could not be conﬁrmed so
far (Sullivan et al., 2009). In this context, a higher proportion of rVSV-
ZEBOV-induced IgM antibodies in contrast to IgG were recently de-
scribed suggesting a potential over-estimation of the impact of vac-
cine-induced IgG antibodies (Khurana et al., 2016).
Data from pre-clinical studies indicated involvement of humoral and
cellular mechanisms in vaccine-mediated immune protection (Marzi et
al., 2013; Jones et al., 2007; Sullivan et al., 2003; Sullivan et al., 2009).
However, the role of cell-mediated responses induced by rVSV-ZEBOV,
but also in natural EBOV-infection has scarcely been analyzed. Some lim-
ited T-cell data from our group and others exist that characterize Ebola
GP-speciﬁc T cells from EVD-survivors, rVSV-ZEBOV immunized NHP,
a rVSV-ZEBOV-PEP case as well as from individuals immunized by ade-
novirus-vectored Ebola vaccines (Jones et al., 2005; Dahlke et al., 2017;
Ruibal et al., 2016; McElroy et al., 2015; Marzi et al., 2015; De Santis et
al., 2016; Qiu et al., 2009). All studies commonly identiﬁed a predomi-
nance of EBOV GP-speciﬁc CD8+ over CD4+ T cells that express IL2,IFNγ and/or TNFα (Jones et al., 2005; McElroy et al., 2015; Marzi et al.,
2015; De Santis et al., 2016; Qiu et al., 2009). Our study revealed detect-
able Ebola GP-speciﬁc T cells with a low proportion of polyfunctional re-
sponses, which is in line with ﬁndings observed in rVSV-ZEBOV-
immunized NHP and EVD-survivors (McElroy et al., 2015; Dahlke et
al., 2017), but also for the vaccine HPV3/EboGP (Meyer et al., 2015).
While IFNγ induction has been shown as an immune correlate for
some diseases, it might play a minor role in EVD-protection. Animal
studies revealed that cytolytic activity may correlate better with EVD-
clearance than IFNγ secrection (Meyer et al., 2015; Gupta et al., 2005;
Wilson andHart, 2001). In linewith this, we also found little Ebola-spe-
ciﬁc IFNγ secretion but dose-dependent and signiﬁcant induction of an-
tigen-speciﬁc CTL-responses asmeasured by CD107a. However, for lack
of data evaluating the capacity of antigen-speciﬁc T cells to protect
against EBOV-challenge, it remains unknown or equivocal whether
these cells contribute signiﬁcantly to protection. The question, to what
extent Ebola-speciﬁc T cells of low-to-moderate magnitude contribute
to vaccine-mediated immune protection remains unanswered andwar-
rants further study. Of note, we observed a general activation of T cells
in the vaccinees, which seems to be non-Ebola speciﬁc and might very
well be a hallmark of immunization with replicating vaccines as a sim-
ilar phenomenon has been observed for YFV-17D (Blom et al., 2013;
Miller et al., 2008).
While ﬂow cytometry- and ELISpot-based investigation allows for the
assessment of only a limited number of cytokines,multiplexed LUMINEX-
analysis supports in-depth inquiry of a broad array of rVSV-ZEBOV in-
duced signaling molecules. We observed a substantial secretion upon
stimulation with Ebola GP OLP-pools. In particular, cytokines belonging
to TH1-response revealed a signiﬁcant induction in subjects immunized
with 2 × 107 PFU. The cytokines IL2, IFNγ and TNFα, which activate
Fig. 4. Kinetics of plasmablasts and T-cell activation in response to rVSV-ZEBOV immunization. a) Plasmablasts peaked at day 7 post vaccination in all dose groups. B cells were stained
using antibodies against CD19, CD24 and CD38. Representative contour plots depict B-cell subsets of naïve (CD19+CD24low/intermCD38interm), memory (CD19+CD24−/interm/
highCD38low/interm), transitional (CD19+CD24+CD38high) and plasmablasts (CD19+CD24−CD38high). Numbers in contour plots represent the percentage of plasmablasts of CD19+ B
cells. b) Percentages of CD19+CD24−CD38high over time in immunized subjects. Each dot and line depicts one subject (3 × 105 PFU: n = 10; 3 × 106 PFU: n = 8; 2 × 107 PFU: n = 9).
c) Graph highlights the fold induction of plasmablasts at day 7 compared to day 0. Each dot represents one subject (bar graph, line: median value). d) T-cell activation in subjects early
after vaccination. Activation was analyzed by HLA DR and CD38 staining. Representative contour plots depict the gating strategy for activation of CD4+ (upper plot) and CD8+ T cells
(lower plot). e) Percentages of HLA DR+CD38+ of CD4+ (upper row) and CD8+ T cells (lower row) are represented in the graphs. Each dot and line represents one subject. (3 × 105
PFU: n = 10; 3 × 106 PFU: n = 6; 2 × 107 PFU: n = 8). Statistical analysis was performed using Mann-Whitney-Wilcoxon test (*p b 0.05; **p b 0.01; ***p b 0.005).
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cells, were signiﬁcantly induced. Of note, the highest dose cohort also sig-
niﬁcantly induced IP10 (Supplementary Appendix, Figs. S9 and S10),
which, based on our unpublished data, might also serve as a predictivemarker for GP-speciﬁc antibody titers (unpublished data; Rechtien
et al.).
In addition to cytokine induction, our correlogram analysis data re-
vealed that different vaccine doses generate a new order within the
Fig. 5. Ebola GP-speciﬁc T-cell responses. Kinetics of antigen-speciﬁc CD8+ T-cell responses. a) Four different peptide pools (GP1a, GP1b, GP2, SP) that cover the whole Ebola GP protein
(Kikwit) were used for PBMC stimulation. Graphs represent frequencies (%) of total cytokine responses of CD8+ T cells (IFNγ, TNFα, IL2, MIP1β). Each dot represents one subject. (3 × 105
PFU: n= 10; 3 × 106 PFU: n= 7; 2 × 107 PFU: n= 8) (Box andWhiskers, Min to Max, Line: median) b) Fold induction of total cytokines of CD8+ T cells from day 0 to day 56 (Bar graph,
line: median value). c) Piecharts represent composition of cytokines induced by all four peptide pools. They show the average values of CD8+ T-cell responses of day 56 of the 2 × 107 PFU
dose cohort.
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with the vaccine dose, as we observed strongest correlations between
signaling molecules in the 2 × 107 PFU cohort. This is concordant with
and extends data by Farooq et al., in which 10 cytokines were analyzed
in rVSV-ZEBOV immunized subjects (Farooq et al., 2016). While direct
comparison is limited by the different numbers of cytokines analyzed(27 in the present study versus 10 cytokines), both studies revealed
that the interlocked network increases with vaccine dose. Farooq and
colleagues did not detect a correlation of TNFα and IFNγ aswe have ob-
served, but both studies identiﬁed a cluster consisting of IL4, IL6, IL1b
and TNFα. Although neither of these molecules nor their correlation
have so far been associated with EVD protection, it can be speculated
Fig. 6. CTL-responses following rVSV-ZEBOV vaccination. a) Degranulation of CD8+ T cells was measured by CD107a staining. Graphs depict the sum of frequency of CD107a expression
induced by all four peptide pools (GP1a, GP1b, GP2, SP) (Box and Whiskers, Min to Max, Line: median). b) The breadth of peptide pool responses increases by vaccine dose. An assay
response was determined by 3-fold over the background. The darker the grey, the more peptide pool responses, the higher the breadth of response. Statistical analysis was performed
using Mann-Whitney-Wilcoxon test (*p b 0.05; **p b 0.01; ***p b 0.005).
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the disease.
As the licensing process of the vaccine is currently underway, the as-
pect of variable responses to rVSV-ZEBOV in individuals with different
genetic background, especially in individuals of African descent, re-
quires attention. Our study exclusively included participants of Europe-
an descent except one of Asian descent. Consequently, the results
presented here cannot address this issue. However, our previous
study, in which parts of our clinical data were reported, revealed only
minor differences in antibody titers from subjects with African and Eu-
ropean descent (Agnandji et al., 2016). While this raising the possibility
that similar effects may hold true for cellular responses, this question
warrants further study.
In summary, we here report a side-by-side description of humoral
and cell-mediated responses, including Ebola-speciﬁc T cells following
immunization with the ﬁrst Ebola vaccine candidate demonstrating ef-
ﬁcacy in humans. We delineate a comprehensive human immune pro-
ﬁle of rVSV-ZEBOV, for which very limited human data exist,
especially as it also represents a new vaccine vector platform in
human use. While no strong dose-dependence was identiﬁed with re-
spect to safety, lymphocyte dynamics and binding antibodies, our data
support the usage of 2 × 107 PFU based on EBOV GP-speciﬁc T-cell re-
sponses and cytokine proﬁles, underscoring our previous data suggest-
ing higher neutralizing antibody titers in the 2 × 107 PFU dose cohorts
(Agnandji et al., 2016). Since the exact roles of neutralizing antibodies,
cell-mediated responses and cytokines in EVD-protection remain un-
known, it is difﬁcult to conclude from these whether higher vaccine
doses are required for optimal protection.
In conclusion, our results provide critical new insight into cellular
immunity following rVSV-ZEBOV vaccination and contribute to our un-
derstanding of immunity elicited by this novel vaccine vector platform
in humans.While antibodies usually protect against infection, cytokines
as well as CD8+ T cells might be critical factors to terminate virus-repli-
cation and thereby control viremia and infection. These data contribute
importantly to our understanding of EVD-immunity andmay lay a foun-
dation for further strategic vaccine design in the context of next gener-
ation emergency vaccines.Funding Sources
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